STAAR Surgical Company STAA R2K

Healthcare · Medical Instruments & Supplies · United States

https://www.staar.com

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Market & Price

Market Cap

$1.49B

Current Price

$29.89

High / Low (52W)

$33.34 / $16.10

Beta

1.20

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

30.27

PEG Ratio

0.76

Book Value

$6.97

Price to Book

4.29

P/S

5.13

EV/EBITDA

93.83

Dividend Yield

Profitability & Returns

ROCE

-11.99%

ROE

-5.99%

ROA

0.88%

Profit Margin

-7.24%

Op Margin

18.69%

EPS (Latest Qtr)

$0.10

EPS (TTM)

$-0.42

Balance Sheet & Liquidity

Debt/Equity

0.11

Quick Ratio

4.09

Current Ratio

5.12

Debt

$37.29M

Total Assets

$451.68M

Current Assets

$311.55M

Working Capital

$243.04M

Ownership

Promoter Holding

0.72%

Chg in Prom Hold

FII / Inst Holding

113.85%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.36B

Total Revenue (TTM)

$290.38M

EBITDA

$14.51M

Free Cash Flow

$-17.51M

Operating Cash Flow

$-50.19M

Shares Outstanding

49.79M

Gross Margin

76.89%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-5.57%

Profit 5Y

-100.94%

Revenue (YoY)

119.60%

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -5.6% CAGR over 5 years.
Earnings shrank at -100.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	STAA STAAR Surgical Company R2K	29.89	-	$1.49B	-	-11.99%	-5.99%	-5.57%	-100.94%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jan 2016	Apr 2016	Jul 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Jan 2020	Apr 2020	Jul 2020	Oct 2020	Jan 2021	Apr 2021	Jul 2021	Oct 2021	Dec 2021	Apr 2022	Jul 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Apr 2026
Revenue	-	-	-	-	-	-	-	-	-	5.93M	6.61M	5.35M	-	4.80M	5.23M	5.24M	-	5.85M	4.47M	5.59M	-	4.25M	3.13M	-	-	-	-	-	-	-	-	-	-	-	42.59M	44.32M	94.73M	57.80M	93.52M	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.58M	11.52M	16.86M	14.06M	24.66M	-
Gross Profit	14.66M	12.99M	14.63M	14.87M	15.88M	14.58M	15.47M	16.85M	17.38M	19.43M	25.23M	23.86M	22.99M	24.18M	29.90M	29.05M	28.82M	24.76M	24.43M	34.87M	34.30M	39.14M	49.20M	45.30M	44.99M	49.26M	63.87M	60.46M	57.56M	70.73M	63.64M	61.03M	78.41M	-	28.00M	32.80M	77.88M	43.74M	68.86M	68.86M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	62.74M	57.52M	53.43M	54.68M	51.46M	-
Operating Income	-	-10.05M	-2.14M	-1.72M	-	-2.08M	-1.32M	1.04M	-	799.00K	3.03M	1.58M	-	1.56M	4.61M	3.33M	-	-1.14M	-1.05M	4.88M	-	7.47M	10.65M	7.84M	-	12.11M	17.02M	13.71M	2.80M	8.60M	6.29M	-2.28M	11.90M	-	-34.74M	-24.72M	24.44M	-10.94M	17.40M	7.98M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-32.35M	-22.79M	26.44M	-8.52M	19.61M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-54.49M	-25.91M	18.79M	-20.65M	8.22M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-275.00K	-9.10M	9.91M	-2.34M	3.01M	-
Net Income	-842.00K	-8.04M	-2.14M	-1.78M	-167.00K	-2.20M	-971.00K	1.17M	-138.00K	583.00K	1.83M	1.46M	1.10M	1.37M	3.91M	2.39M	6.38M	-134.00K	-1.17M	3.89M	3.33M	4.99M	8.57M	6.02M	4.92M	9.60M	13.04M	10.26M	2.71M	6.06M	4.82M	-3.34M	7.38M	-	-54.21M	-16.81M	8.88M	-18.31M	5.21M	5.21M
Diluted EPS	-	-	-	-0.04	-	-0.05	-0.02	0.03	-	0.01	0.04	0.03	0.02	0.03	0.08	0.05	0.14	0.00	-0.03	0.08	0.07	0.10	0.17	0.12	0.10	0.19	0.26	0.21	0.05	0.12	0.10	-0.07	0.15	-	-1.10	-0.34	0.18	-0.37	0.10	0.10
R&D Expense	-	6.91M	4.66M	4.45M	-	4.78M	4.77M	4.59M	-	5.41M	5.35M	5.57M	-	5.63M	6.10M	6.16M	-	6.90M	7.31M	8.75M	-	8.26M	8.26M	8.27M	-	7.94M	8.64M	9.62M	10.31M	11.76M	11.47M	13.38M	11.87M	12.25M	11.34M	10.26M	9.21M	-	-	9.93M

Profit & Loss (Annual)

Figures in USD.

Metric	Jan 2010	Dec 2010	Dec 2011	Dec 2012	Jan 2014	Jan 2015	Jan 2016	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Jan 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025	Jan 2026
Revenue	-	-	-	-	-	-	-	23.32M	22.29M	22.87M	20.86M	22.05M	-	284.39M	322.42M	313.90M	239.44M	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	61.01M	69.76M	74.32M	57.02M	-
Gross Profit	31.32M	35.08M	42.37M	44.29M	50.31M	48.82M	52.72M	58.37M	64.28M	91.51M	111.95M	118.36M	-	223.38M	252.65M	239.58M	182.42M	182.42M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	179.58M	224.55M	252.19M	228.37M	-
Operating Income	-4.88M	-2.60M	2.78M	-1.22M	700.00K	-8.03M	-5.34M	-12.65M	-3.63M	6.59M	11.85M	6.77M	-	43.80M	28.10M	-12.61M	-45.95M	-91.71M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	48.31M	33.22M	-5.72M	-37.22M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	45.55M	33.70M	-9.05M	-82.26M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	5.89M	12.35M	11.16M	-1.81M	-
Net Income	-6.20M	53.00K	1.35M	-1.76M	398.00K	-8.39M	-6.53M	-12.13M	-2.14M	4.97M	14.05M	5.91M	-	39.66M	21.35M	-20.21M	-80.45M	-80.45M
Diluted EPS	-0.19	0.00	0.04	-0.05	0.01	-0.22	-0.17	-0.30	-0.05	0.11	0.30	0.12	-	0.79	0.43	-0.41	-1.62	-1.62
R&D Expense	5.89M	5.72M	5.87M	6.44M	6.71M	12.36M	14.76M	20.67M	20.04M	22.03M	25.30M	31.92M	33.86M	35.98M	40.48M	45.32M	-	40.05M

Compounded Sales Growth

5 Years:	-5.57%
1 Year:	119.60%

Compounded Profit Growth

5 Years:	-100.94%
1 Year:	-

Stock Price Performance

1 Year:	+67.83%
6 Months:	+14.04%
3 Months:	+50.20%
1 Month:	+17.31%

Balance Sheet (Annual)

Figures in USD.

Metric	Jan 2009	Dec 2009	Jan 2010	Dec 2010	Dec 2011	Dec 2012	Jan 2014	Jan 2015	Jan 2016	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Jan 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025	Jan 2026
Total Assets	-	-	-	40.59M	49.01M	54.76M	61.93M	58.91M	62.95M	65.48M	67.93M	167.34M	207.52M	257.42M	-	418.82M	488.69M	509.52M	451.68M	451.68M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	311.72M	365.27M	367.94M	311.55M	-
Cash & Equivalents	4.99M	6.33M	6.33M	9.38M	16.58M	21.68M	22.95M	13.01M	13.40M	14.00M	18.52M	103.88M	119.97M	152.45M	-	86.48M	183.04M	144.16M	153.15M	153.15M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.16M	35.13M	43.30M	55.50M	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	62.45M	94.70M	77.90M	50.06M	-
Total Liabilities	-	-	-	18.16M	19.55M	23.02M	23.08M	21.81M	24.11M	27.57M	25.00M	34.91M	47.64M	60.19M	-	82.71M	102.74M	112.19M	107.49M	107.49M
Current Liabilities	-	-	-	13.45M	14.02M	17.95M	18.41M	16.37M	17.89M	21.07M	19.09M	27.73M	34.48M	41.24M	-	51.72M	65.04M	70.31M	68.50M	68.50M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.04M	35.83M	38.74M	38.35M	-
Total Equity	16.03M	21.07M	21.07M	22.43M	29.46M	31.74M	38.85M	37.10M	38.85M	37.91M	42.94M	132.43M	159.88M	197.22M	-	336.11M	385.95M	397.33M	344.18M	344.18M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48.21M	48.84M	49.29M	49.78M	-

Cash Flows (Annual)

Figures in USD.

Metric	Jan 2010	Dec 2010	Dec 2011	Dec 2012	Jan 2014	Jan 2015	Jan 2016	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Jan 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025	Jan 2026
Operating Cash Flow	1.43M	-4.42M	5.35M	3.22M	-	-	-2.16M	1.05M	2.85M	12.77M	25.80M	20.95M	-	35.72M	14.59M	15.72M	-34.23M	-34.23M
Investing Cash Flow	-7.61M	18.77M	-889.00K	-2.15M	-	-	-2.04M	-3.21M	-1.05M	-2.25M	-10.18M	-8.40M	-	-156.38M	74.35M	-59.22M	46.34M	46.34M
Financing Cash Flow	7.36M	-11.52M	2.77M	4.28M	-	-	4.58M	2.95M	2.44M	74.64M	149.00K	19.57M	-	8.30M	7.42M	5.72M	-4.55M	-4.55M
Capital Expenditure	-553.00K	-320.00K	-962.00K	-2.27M	-3.45M	-4.05M	-2.04M	-3.21M	-1.05M	-2.25M	-10.10M	-8.40M	-	-18.11M	-18.19M	-23.39M	-5.82M	-5.82M
Free Cash Flow	874.00K	-4.74M	4.38M	946.00K	-	-	-4.21M	-2.16M	1.81M	10.52M	15.70M	12.55M	-	17.61M	-3.59M	-7.67M	-40.05M	-40.05M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-112.36M	96.36M	-37.77M	7.55M	-
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.46M

Ratios (Annual)

Figures in %.

Metric	Jan 2010	Dec 2010	Dec 2011	Dec 2012	Jan 2014	Jan 2015	Jan 2016	Dec 2016	Dec 2017	Dec 2018	Jan 2020	Jan 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025	Jan 2026
Gross Margin %	-	-	-	-	-	-	-	250.3%	288.4%	400.1%	536.6%	536.7%	-	78.5%	78.4%	76.3%	76.2%	-
Operating Margin %	-	-	-	-	-	-	-	-54.3%	-16.3%	28.8%	56.8%	30.7%	-	15.4%	8.7%	-4.0%	-19.2%	-
Net Margin %	-	-	-	-	-	-	-	-52.0%	-9.6%	21.7%	67.3%	26.8%	-	13.9%	6.6%	-6.4%	-33.6%	-
ROE %	-29.4%	0.2%	4.6%	-5.6%	1.0%	-22.6%	-16.8%	-32.0%	-5.0%	3.8%	8.8%	3.0%	-	11.8%	5.5%	-5.1%	-23.4%	-23.4%
ROCE %	-	-9.6%	8.0%	-3.3%	1.6%	-18.9%	-11.8%	-28.5%	-7.4%	4.7%	6.8%	3.1%	-	11.9%	6.6%	-2.9%	-12.0%	-23.9%

Shareholding Pattern

Insiders

0.72%

Institutions

113.85%

Public Float

114.68%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Broadwood Capital, Inc.	32.38%	16.12M	$481.94M
2	Blackrock Inc.	13.39%	6.67M	$199.25M
3	Yunqi Capital Ltd	6.54%	3.26M	$97.36M
4	Madison Avenue Partners, LP	4.90%	2.44M	$72.98M
5	Vanguard Portfolio Management LLC	4.27%	2.12M	$63.47M
6	State Street Corporation	3.68%	1.83M	$54.79M
7	Vanguard Capital Management LLC	3.40%	1.69M	$50.53M
8	Anatole Investment Management Ltd	3.22%	1.60M	$47.87M
9	Morgan Stanley	3.01%	1.50M	$44.82M
10	Goldman Sachs Group Inc	2.15%	1.07M	$31.98M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for STAA

No recent headlines available.

STAA · Healthcare